Last reviewed · How we verify
68Ga-NOTA-SNA002
At a glance
| Generic name | 68Ga-NOTA-SNA002 |
|---|---|
| Also known as | Positron Emission Tomography |
| Sponsor | SmartNuclide Biopharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Clinical Trial of 68Ga-NOTA-SNA002 (PHASE1)
- [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 68Ga-NOTA-SNA002 CI brief — competitive landscape report
- 68Ga-NOTA-SNA002 updates RSS · CI watch RSS
- SmartNuclide Biopharma portfolio CI